在临床试验了两代的亚硝脲类化合物:第一代为BNCU、CCNU 和MeCCNU,对何杰金氏和非何杰金氏淋巴瘤、结肠直肠癌和脑瘤有抑制作用;第二代为糖甙亚硝脲,如吡葡亚硝脲(Chlorozotocin,CZT 或DCNU)、呋核亚硝脲(RFCNU)和吡核亚硝脲(RP-CNU),对未经治疗的黑色素瘤、某些血液肿瘤、结肠直肠癌以及来源不明的转移瘤均有活性;其血液系统毒性较第一代亚硝脲低,这可能与它们对L1210白血病的量-效曲线有关。第二代亚硝脲类对L1210白血病的 In clinical trials of two generations of nitrosourea compounds: the first generation of BNCU, CCNU and MeCCNU, Hodgkin’s and non-Hodgkin’s lymphoma, colorectal cancer and brain tumor inhibition; the second generation of Glycoside nitrosoureas, such as Chlorozotocin (CZT or DCNU), Riboflavin (RFCNU), and Pyrantel Nitrosamine (RP-CNU), have been shown to treat untreated melanoma, some Hematologic, colorectal, and metastatic tumors of unknown origin are active; their hematologic toxicity is lower than that of the first generation of nitrosourea, which may be related to their dose-response curves for L1210 leukemia. Second-generation nitrosourea on L1210 leukemia